These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 23541490)

  • 1. Cardiotrophin-1 (CTF1) ameliorates glucose-uptake defects and improves memory and learning deficits in a transgenic mouse model of Alzheimer's disease.
    Wang D; Li X; Gao K; Lu D; Zhang X; Ma C; Ye F; Zhang L
    Pharmacol Biochem Behav; 2013 Jun; 107():48-57. PubMed ID: 23541490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Effects of Cardiotrophin-1 on Early Synaptic Mitochondrial Dysfunction and Synaptic Pathology in APPswe/PS1dE9 Mice.
    Wang D; Liu X; Liu Y; Li S; Wang C
    J Alzheimers Dis; 2017; 59(4):1255-1267. PubMed ID: 28731433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer's disease: relationships to beta-amyloid deposition and neurotransmitter abnormalities.
    Savonenko A; Xu GM; Melnikova T; Morton JL; Gonzales V; Wong MP; Price DL; Tang F; Markowska AL; Borchelt DR
    Neurobiol Dis; 2005 Apr; 18(3):602-17. PubMed ID: 15755686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A modified formulation of Chinese traditional medicine improves memory impairment and reduces Aβ level in the Tg-APPswe/PS1dE9 mouse model of Alzheimer's disease.
    Jeon S; Bose S; Hur J; Jun K; Kim YK; Cho KS; Koo BS
    J Ethnopharmacol; 2011 Sep; 137(1):783-9. PubMed ID: 21762767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Visuo-spatial learning and memory deficits on the Barnes maze in the 16-month-old APPswe/PS1dE9 mouse model of Alzheimer's disease.
    O'Leary TP; Brown RE
    Behav Brain Res; 2009 Jul; 201(1):120-7. PubMed ID: 19428625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble Aβ levels correlate with cognitive deficits in the 12-month-old APPswe/PS1dE9 mouse model of Alzheimer's disease.
    Zhang W; Hao J; Liu R; Zhang Z; Lei G; Su C; Miao J; Li Z
    Behav Brain Res; 2011 Sep; 222(2):342-50. PubMed ID: 21513747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Illite improves memory impairment and reduces Aβ level in the Tg-APPswe/PS1dE9 mouse model of Alzheimer׳s disease through Akt/CREB and GSK-3β phosphorylation in the brain.
    Jeon S; Park JE; Lee J; Liu QF; Jeong HJ; Pak SC; Yi S; Kim MH; Kim CW; Park JK; Kim GW; Koo BS
    J Ethnopharmacol; 2015 Feb; 160():69-77. PubMed ID: 25457987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progressive Spatial Memory Impairment, Brain Amyloid Deposition and Changes in Serum Amyloid Levels as a Function of Age in APPswe/PS1dE9 Mice.
    Fu L; Sun Y; Guo Y; Yu B; Zhang H; Wu J; Yu X; Wu H; Kong W
    Curr Alzheimer Res; 2018; 15(11):1053-1061. PubMed ID: 29984654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dickkopf 3 (Dkk3) Improves Amyloid-β Pathology, Cognitive Dysfunction, and Cerebral Glucose Metabolism in a Transgenic Mouse Model of Alzheimer's Disease.
    Zhang L; Sun C; Jin Y; Gao K; Shi X; Qiu W; Ma C; Zhang L
    J Alzheimers Dis; 2017; 60(2):733-746. PubMed ID: 28922151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in the brain and plasma Aβ peptide levels with age and its relationship with cognitive impairment in the APPswe/PS1dE9 mouse model of Alzheimer's disease.
    Izco M; Martínez P; Corrales A; Fandos N; García S; Insua D; Montañes M; Pérez-Grijalba V; Rueda N; Vidal V; Martínez-Cué C; Pesini P; Sarasa M
    Neuroscience; 2014 Mar; 263():269-79. PubMed ID: 24447596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative studies using the Morris water maze to assess spatial memory deficits in two transgenic mouse models of Alzheimer's disease.
    Edwards SR; Hamlin AS; Marks N; Coulson EJ; Smith MT
    Clin Exp Pharmacol Physiol; 2014 Oct; 41(10):798-806. PubMed ID: 25115283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple inflammatory pathways are involved in the development and progression of cognitive deficits in APPswe/PS1dE9 mice.
    Zhang W; Bai M; Xi Y; Hao J; Zhang Z; Su C; Lei G; Miao J; Li Z
    Neurobiol Aging; 2012 Nov; 33(11):2661-77. PubMed ID: 22277264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alterations in Cerebral Cortical Glucose and Glutamine Metabolism Precedes Amyloid Plaques in the APPswe/PSEN1dE9 Mouse Model of Alzheimer's Disease.
    Andersen JV; Christensen SK; Aldana BI; Nissen JD; Tanila H; Waagepetersen HS
    Neurochem Res; 2017 Jun; 42(6):1589-1598. PubMed ID: 27686658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel glycogen synthase kinase-3 inhibitor 2-methyl-5-(3-{4-[(S )-methylsulfinyl]phenyl}-1-benzofuran-5-yl)-1,3,4-oxadiazole decreases tau phosphorylation and ameliorates cognitive deficits in a transgenic model of Alzheimer's disease.
    Onishi T; Iwashita H; Uno Y; Kunitomo J; Saitoh M; Kimura E; Fujita H; Uchiyama N; Kori M; Takizawa M
    J Neurochem; 2011 Dec; 119(6):1330-40. PubMed ID: 21992552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Locomotor activity, emotionality, sensori-motor gating, learning and memory in the APPswe/PS1dE9 mouse model of Alzheimer's disease.
    O'Leary TP; Hussin AT; Gunn RK; Brown RE
    Brain Res Bull; 2018 Jun; 140():347-354. PubMed ID: 29870778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Valproic Acid Modifies Synaptic Structure and Accelerates Neurite Outgrowth Via the Glycogen Synthase Kinase-3β Signaling Pathway in an Alzheimer's Disease Model.
    Long ZM; Zhao L; Jiang R; Wang KJ; Luo SF; Zheng M; Li XF; He GQ
    CNS Neurosci Ther; 2015 Nov; 21(11):887-97. PubMed ID: 26385876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A detailed analysis of the early context extinction deficits seen in APPswe/PS1dE9 female mice and their relevance to preclinical Alzheimer's disease.
    Bonardi C; de Pulford F; Jennings D; Pardon MC
    Behav Brain Res; 2011 Sep; 222(1):89-97. PubMed ID: 21440575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression Profiling of Cytokine, Cholinergic Markers, and Amyloid-β Deposition in the APPSWE/PS1dE9 Mouse Model of Alzheimer's Disease Pathology.
    Reale M; D'Angelo C; Costantini E; Di Nicola M; Yarla NS; Kamal MA; Salvador N; Perry G
    J Alzheimers Dis; 2018; 62(1):467-476. PubMed ID: 29439355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of Bdnf gene deficiency to the memory impairment and brain pathology of APPswe/PS1dE9 mouse model of Alzheimer's disease.
    Rantamäki T; Kemppainen S; Autio H; Stavén S; Koivisto H; Kojima M; Antila H; Miettinen PO; Kärkkäinen E; Karpova N; Vesa L; Lindemann L; Hoener MC; Tanila H; Castrén E
    PLoS One; 2013; 8(7):e68722. PubMed ID: 23844236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Powerful beneficial effects of benfotiamine on cognitive impairment and beta-amyloid deposition in amyloid precursor protein/presenilin-1 transgenic mice.
    Pan X; Gong N; Zhao J; Yu Z; Gu F; Chen J; Sun X; Zhao L; Yu M; Xu Z; Dong W; Qin Y; Fei G; Zhong C; Xu TL
    Brain; 2010 May; 133(Pt 5):1342-51. PubMed ID: 20385653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.